LNAI
LunaiยทNASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
LNAI Profile
Lunai Bioworks Inc.
A data-driven biotech company leveraging artificial intelligence to integrate multi-dimensional biological data for developing diagnostic and therapeutic solutions for diseases such as Alzheimer's
Biological Technology
01/18/2011
12/10/2018
NASDAQ Stock Exchange
29
06-30
Common stock
2080 Century Park East, Suite 906, Los Angeles, CA 90067
--
Lunai Bioworks Inc., incorporated in Delaware on January 18, 2011, operates through three subsidiaries: Renovaro Biosciences, Renovaro Cube and BioSymetrics. Renovaro Cube, including GediCube Intl. Ltd., and its subsidiaries, were acquired on February 13, 2024, and BioSymetrics and its subsidiaries were acquired on April 8, 2025. Renovaro Biosciences, the company's biotechnology division, focuses on the development of allogeneic cell and gene therapies designed to strengthen the immune response and designed to support long-term cancer remission. Following the acquisition of GediCube INTL., Lunai has increasingly emphasized molecular diagnostic and oncology technologies. The company's development areas include innovative therapeutic vaccination platforms for solid tumors such as pancreatic cancer, liver cancer, triple-negative breast cancer, and head and neck cancer. Its approach utilizes engineered donor cells and molecular diagnostic techniques that have the potential to provide "off-the-shelf" treatment options that reduce the delay between diagnosis and treatment.
